Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
In our 30+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
Gary D. Novack, Ph.D., Clinical Professor and Vice Chair for Collaborative Research in the Department of Ophthalmology & Vision Science, recently published his 400th paper. Dr. Novack earned his Ph.D. in Pharmacology and Toxicology from UC Davis. His early papers were in his original field of neuroscience, about treatment of epilepsy,
Dr. Novack presents at Duke University Eye Center In November 2024, Dr. Novack was at the Duke University Eye Center where he gave a talk on “Translation from ophthalmic RESEARCH to ophthalmic PRODUCTS”. Attending were many scientists who, one day, hope to translate their ideas into therapeutics for patients.
Just returned from my ~43rd American Academy of Ophthalmology meeting in Chicago. where I saw many colleagues and friends while getting up to date on ophthalmology from anterior to posterior. i was pleased to see presentations on clinical data from many of our clients, and to discuss many projects for